Clearside Biomedical Inc
CLSD0.418USD
+0.034+8.85%
Market hours （ET）Quotes delayed by 15 min
32.31MMarket Cap
LossP/E TTM
More Details of Clearside Biomedical Inc Company
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Company Info
Ticker SymbolCLSD
Company nameClearside Biomedical Inc
IPO dateJun 02, 2016
CEO- -
Number of employees32
Security typeOrdinary Share
Fiscal year-endJun 02
Address900 North Point Parkway
CityALPHARETTA
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code30005
Phone16782703631
Websitehttps://clearsidebio.com/
Ticker SymbolCLSD
IPO dateJun 02, 2016
CEO- -
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Charles A. Deignan
Mr. Charles A. Deignan
Principal Financial Officer
Principal Financial Officer
373.10K
+10.57%
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Director
Independent Director
93.00K
--
Dr. Christy L. Shaffer, Ph.D.
Dr. Christy L. Shaffer, Ph.D.
Independent Director
Independent Director
78.45K
+1683.07%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
51.04K
--
Dr. Benjamin (Ben) Yerxa, Ph.D.
Dr. Benjamin (Ben) Yerxa, Ph.D.
Independent Director
Independent Director
17.96K
--
Dr. George Lasezkay, Pharm.D.
Dr. George Lasezkay, Pharm.D.
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Jenny Kobin
Ms. Jenny Kobin
Investor Relations
Investor Relations
--
--
Mr. Clay Bernardin Thorp
Mr. Clay Bernardin Thorp
Independent Director
Independent Director
--
--
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
--
--
Dr. Victor Chong
Dr. Victor Chong
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Charles A. Deignan
Mr. Charles A. Deignan
Principal Financial Officer
Principal Financial Officer
373.10K
+10.57%
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Director
Independent Director
93.00K
--
Dr. Christy L. Shaffer, Ph.D.
Dr. Christy L. Shaffer, Ph.D.
Independent Director
Independent Director
78.45K
+1683.07%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
51.04K
--
Dr. Benjamin (Ben) Yerxa, Ph.D.
Dr. Benjamin (Ben) Yerxa, Ph.D.
Independent Director
Independent Director
17.96K
--
Dr. George Lasezkay, Pharm.D.
Dr. George Lasezkay, Pharm.D.
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, May 14
Updated: Wed, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Whitmore (Bradford T)
5.49%
Wiles (Stephen Boyd)
5.15%
The Vanguard Group, Inc.
3.61%
Grace Brothers Management, LLC
2.90%
Carmignac Gestion
1.94%
Other
80.90%
Shareholders
Shareholders
Proportion
Whitmore (Bradford T)
5.49%
Wiles (Stephen Boyd)
5.15%
The Vanguard Group, Inc.
3.61%
Grace Brothers Management, LLC
2.90%
Carmignac Gestion
1.94%
Other
80.90%
Shareholder Types
Shareholders
Proportion
Individual Investor
13.02%
Investment Advisor
6.44%
Hedge Fund
4.36%
Investment Advisor/Hedge Fund
3.62%
Research Firm
0.18%
Bank and Trust
0.06%
Pension Fund
0.05%
Other
72.26%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
122
21.55M
27.74%
+95.39K
2025Q1
129
24.68M
31.84%
-269.80K
2024Q4
133
21.24M
28.00%
-3.85M
2024Q3
136
22.15M
29.40%
-4.49M
2024Q2
138
27.49M
37.28%
-3.24M
2024Q1
137
28.99M
41.38%
+6.58M
2023Q4
140
20.76M
33.50%
-5.62M
2023Q3
149
20.47M
33.45%
-8.00M
2023Q2
151
21.16M
34.64%
-7.49M
2023Q1
151
21.57M
35.57%
-8.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Whitmore (Bradford T)
4.27M
5.49%
-226.06K
-5.03%
Dec 31, 2024
Wiles (Stephen Boyd)
4.00M
5.15%
+4.00M
--
Mar 31, 2025
The Vanguard Group, Inc.
2.81M
3.61%
--
--
Mar 31, 2025
Grace Brothers Management, LLC
2.25M
2.9%
-95.61K
-4.07%
Dec 31, 2024
Carmignac Gestion
1.51M
1.94%
-425.19K
-21.99%
Mar 31, 2025
Geode Capital Management, L.L.C.
792.25K
1.02%
+28.19K
+3.69%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
786.92K
1.01%
-9.71K
-1.22%
Mar 31, 2025
Renaissance Technologies LLC
554.51K
0.71%
-167.28K
-23.18%
Mar 31, 2025
GSA Capital Partners LLP
201.59K
0.26%
+201.59K
--
Mar 31, 2025
Lasezkay (George M)
382.76K
0.49%
--
--
Apr 01, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
AltShares Event-Driven ETF
0%
iShares Micro-Cap ETF
Proportion0%
AltShares Event-Driven ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
